NuProtect: Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A
| ISRCTN | ISRCTN50040185 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN50040185 |
| EudraCT/CTIS number | 2012-002554-23 |
| ClinicalTrials.gov number | NCT01712438 |
| Secondary identifying numbers | GENA-05 |
- Submission date
- 11/09/2013
- Registration date
- 22/10/2013
- Last edited
- 23/05/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Haematological Disorders
Plain English summary of protocol
Background and study aims
FVIII concentrates are the only available treatment for patients with severe haemophilia A. However, patients are at risk of developing resistance (inhibitor) to FVIII, which stops the treatment from working, and patients may also suffer from an allergic reaction. The drug under investigation, human-cl rhFVIII, is a newly developed recombinant FVIII concentrate from a human cell line, which may have less immunogenic potential (ability to provoke an immune response) compared to FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. The main aim of the study is to investigate the immunogenicity of the new product in previously untreated patients with severe haemophilia A. This population is at the highest risk of developing inhibitors. Previous studies of the new product in already treated patients (adults and children) did not show a single case of inhibitor development.
Who can participate?
Previously untreated patients with severe haemophilia A.
What does the study involve?
All patients will receive the newly developed recombinant FVIII concentrate injection. The study involves regular blood sampling to screen for inhibitors. All patients adverse events are documented.
What are the possible benefits and risks of participating?
Human-cl rhFVIII may have less immunogenic potential compared to recombinant FVIII concentrates from hamster cell lines or plasma-derived FVIII concentrates. However, as for all FVIII concentrates, patients are at risk of developing an inhibitor to FVIII and may suffer from an allergic reaction.
Where is the study run from?
The study is planned to be conducted at about 45 study sites in 16 countries worldwide.
When is the study starting and how long is it expected to run for?
The study started in March 2013, and is planned to be completed in 2018.
Who is funding the study?
Octapharma AG, Switzerland
Who is the main contact?
Martina Jansen
Octapharma PPG
Clinical Research & Development Haematology
Oberlaaerstrasse 235
1100 Vienna, Austria
Contact information
Scientific
Great Ormond Street Hospital for Children, NHS Trust
Haemophilia Centre
Great Ormond Street
London
WC1N 3JH
United Kingdom
Study information
| Study design | Prospective multicentre multinational open-label non-controlled study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Screening |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A: a prospective, multinational, open-label, non-controlled study |
| Study objectives | Immunogenicity of Human-cl rhFVIII in previously untreated patients with severe haemophilia A is low. |
| Ethics approval(s) | Canada, HIREB Hamilton: 11 March 2013 Germany, Ethics Committee University Münster: 08 July 2013 Spain, Vall d`Hebron, Barcelona: 11 January 2013 France, CPP Ouest V, Nanterre: 07 February 2013 UK, NRES Committee London-Central: 19 February 2013 Georgia, Committee of Institute of Haematology, Tiflis: 17 January 2013 Moldova, National Ethics Committee, Chisinau: 29 January 2013 Poland, EC Medical University Warsaw: 12 February 2013 Russia, Izmailowska EC: 26 June 2013 Ukraine, National Academy of Medical Science: 04 February 2013 |
| Health condition(s) or problem(s) studied | Severe haemophilia A |
| Intervention | There is only one study arm. All patients receive the same investigational medicinal product (IMP) intravenously. The dose, frequency and duration are flexible, and depend on the individual clinical condition of the patient. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Human-cl rhFVIII |
| Primary outcome measure | The immunogenic potential of the IMP. Each patient is tested for the development of inhibitors at treatment start, every three to four exposure days to the IMP, latterly every ten exposure days (latest every three months). |
| Secondary outcome measures | Safety, efficacy and tolerability: Efficacy (by assessing each treatment of a bleeding episode, or the rate of bleeds in case of prophylactic treatment) and safety (adverse events) are observed during the entire study duration, which is planned for a total of 100 exposure days with the IMP, but not longer than 5 years. |
| Overall study start date | 01/03/2013 |
| Completion date | 24/03/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Sex | Male |
| Target number of participants | 100 |
| Key inclusion criteria | 1. Male, no age limitations, but due to the required patient population it can be expected that the majority of patients going to be included are babies and small children. 2. Severe haemophilia A (FVIII:C < 1%) 3. No previous treatment with FVIII concentrates or other blood products containing FVIII 4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted (obtained from the patients parent/legal guardian) |
| Key exclusion criteria | 1. Diagnosis with a coagulation disorder other than haemophilia A 2. Severe liver or kidney disease (alanine amino transferase (ALT) or aspartate transaminase (AST) levels >5 times of upper limit of normal, creatinine >120 µmol/L) 3. Concomitant treatment with any systemic immunosuppressive drug 4. Participation in another interventional clinical study currently or during the past 4 weeks. |
| Date of first enrolment | 01/03/2013 |
| Date of final enrolment | 30/06/2016 |
Locations
Countries of recruitment
- Brazil
- Canada
- Colombia
- England
- France
- Georgia
- Germany
- India
- Moldova
- Morocco
- Poland
- Russian Federation
- Spain
- Ukraine
- United Kingdom
- United States of America
- Venezuela
Study participating centre
WC1N 3JH
United Kingdom
Sponsor information
Industry
Seidenstrasse 2
Lachen
8853
Switzerland
| Website | http://www.octapharma.com |
|---|---|
"ROR" |
https://ror.org/002k5fe57 |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Interim results article | interim results | 01/03/2018 | 14/05/2019 | Yes | No |
| Basic results | EU Clinical Trials Register results | 23/08/2020 | 20/05/2022 | No | No |
| Basic results | ClinicalTrials.gov results | 21/10/2019 | 23/05/2022 | No | No |
Editorial Notes
23/05/2022: ClinicalTrials.gov results added.
20/05/2022: EU Clinical Trials Register results added.
23/04/2020: The overall end date was changed from 31/12/2018 to 24/03/2020.
14/05/2019: Publication reference added.
15/03/2018: The recruitment end date was changed from 31/12/2018 to 30/06/2016.
